Second chance: immune combo aims to reboot lung cancer treatment
NCT ID NCT05401786
First seen Mar 15, 2026 · Last updated May 12, 2026 · Updated 11 times
Summary
This study tests whether giving a different immunotherapy drug (ipilimumab) and targeted radiation can make a standard immunotherapy (anti-PD-1) work again for people with advanced non-small cell lung cancer. About 54 participants will receive this combination to see if it shrinks tumors or stops the cancer from growing for at least 6 months. The goal is to help patients whose cancer stopped responding to standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Antoni van Leeuwenhoek - Netherlands Cancer Institute
Amsterdam, North Holland, 1066 CX, Netherlands
Conditions
Explore the condition pages connected to this study.